Cagrilintide
compound
Long-acting amylin analog; activates AMYR and CTR. In Phase III development. Being combined with semaglutide (CagriSema) in trials showing up to 22-25% weight loss at 32 weeks.
Updated 7/14/2026
Dulaglutide
compound
Once-weekly GLP-1 RA with IgG4-Fc fusion for extended half-life. FDA-approved for T2D and cardiovascular risk reduction. Brand name: Trulicity.
Updated 7/14/2026
Exenatide
compound
First FDA-approved GLP-1 RA. Derived from exendin-4. Available as twice-daily (Byetta) and weekly (Bydureon) formulations. Brand names: Byetta, Bydureon.
Updated 7/14/2026
Liraglutide
compound
First-generation long-acting GLP-1 analog. FDA-approved for T2D (Victoza) and obesity (Saxenda 3mg). Daily injection. Brand names: Victoza, Saxenda.
Updated 7/14/2026
Retatrutide
compound
Investigational triple agonist targeting GLP-1R, GIPR, and glucagon receptor. Phase II trials show up to 24% weight loss at 48 weeks — most powerful peptide weight loss to date.
Updated 7/14/2026